REYKJAVIK, Islanda–(BUSINESS WIRE)–Oculis ha annunciato oggi la chiusura del round di finanziamenti di Serie A, condotta da Brunnur Ventures e Silfurberg. Il nuovo capitale servirà a finanziare lo sviluppo continuo della piattaforma di rilascio dei farmaci a base di nanoparticelle solubilizzanti (solubilizing nanoparticle, SNP) brevetto esclusivo della società, e dei candidati farmaci prodotti dall’azienda, compreso il primo trattamento topico a base di collirio per l’edema maculare diabetico
REYKJAVIK, Island–(BUSINESS WIRE)–Oculis meldete heute den Abschluss einer Serie-A-Finanzierungsrunde unter der Leitung von Brunnur Ventures und Silfurberg. Das frische Kapital dient der Förderung der fortgesetzten Entwicklung der patentierten Drug Delivery Platform von Oculis für solubilisierende Nanopartikel (SNP) und der Arzneimittelkandidaten des Unternehmens, einschließlich der ersten topischen Augentropfen zur Behandlung des diabetischen Makulaödems (DME). SNP Drug Delivery Platform – D
A web-based tool and health care professional training improved communication during patient handoffs and reduced medical errors, according to data published in JAMA Internal Medicine.”Communication among health care personnel is vulnerable to error du…
SAN FRANCISCO — At the American Society of Retina Specialists meeting here, Andrew Antoszyk, MD, discusses results of the DRCR.net Protocol S study, a randomized clinical trial comparing intravitreal ranibizumab with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.
Researchers have documented 35 eyes with severe hemorrhagic occlusive retinal vasculitis after treatment with vancomycin during cataract procedures. Medscape Medical News
SAN FRANCISCO — Sustained delivery of ranibizumab with a port delivery system in patients with neovascular age-related macular degeneration has the potential to improve visual outcomes and reduce the treatment burden associated with anti-VEGF injections, according to a scientific poster presented at the American Society of Retina Specialists meeting. LADDER is a phase 2 study evaluating dosing and functional outcomes with sustained delivery of Lucentis (ranibizumab, Genentech) via the ranibizumab port delivery system (RPDS), which aims to provide longer treatment intervals than any currently available therapy, study co-author Richard F. (Read more...)